Azithromycin Pharmacokinetics in Pregnancy James H. Fischer, Pharm.D., FCCP May 17, 2011.

Slides:



Advertisements
Similar presentations
POPULATION PHARMACOKINETICS OF CEFTRIAXONE IN INTENSIVE CARE UNIT (ICU) ADULT PATIENTS C Le Guellec (1), N Simon (2), D.Garot (3), R. Respaud (1), P Lanotte.
Advertisements

The aim of this study was to characterise the population pharmacokinetics of tacrolimus in paediatric SCT recipients in the first year post-transplant;
The half-life OCT 2010.
Great Ormond Street Hospital for Children NHS Trust The School of Pharmacy UCL INSTITUTE OF CHILD HEALTH Centre for Paediatric Pharmacy Research Drug Development.
Pharmacokinetics and Safety of Metronidazole in Preterm Infants: Validation of Dried Blood Spot Sampling Mario Sampson, PharmD Duke Clinical Research Institute.
Address for contact: FT Musuamba - Department of Clinical Biochemistry, Department of Pharmacokinetics, Metabolism, and Toxicology Av Hippocrate 10, B-1200.
Dosage Regimen Design in Patients with Renal Insufficiency Cont’d Pharmacy 732 Winter, 2001.
Noreen Clark, PhD Molly Gong, MD Melissa Valerio, MPH Sijian Wang, BS Xihong Lin, PhD William Bria, MD Timothy Johnson, MD University of Michigan School.
Pharmacotherapy in the Elderly Paola S. Timiras May, 2007.
Labetalol Pharmacokinetics in Hypertension During Pregnancy James H. Fischer, Pharm.D., FCCP May 17, 2011.
Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April 22, 2003 Pediatric Population Pharmacokinetics Study.
The Association between Antenatal Depression and Adverse Birth Outcomes among Women Receiving Medicaid in Washington State Amelia R. Gavin, PhD School.
Effect of Hepatic Impairment on Sorafenib Pharmacokinetics: Results of a Multicenter, Open-Label, Single-Dose, Phase I Trial J Lettieri, A Mazzu,
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 10 Drug Therapy in Pediatric Patients.
M.G.S.D. The Gestational Diabetes Study in the Mediterranean Region Protocol C. Savona-Ventura Research Management Committee – M.G.S.D.
Factors Affecting Drug Activity Chapter 11 Pages
Figure 1. Diagnostic plots for propofol pharmacokinetics and effect (BIS) in morbidly obese patients including observations versus individual- predictions.
Population Pharmacokinetics
Analysis of Zidovudine pharmacokinetics to determine whether there is a genetic component to the variability and to determine the bioequivalence of seven.
Dosing Regimen Individualization Age. Subcategories Newborn1-7 d Neonate8 d – 2 mo Infant2 mo – 1 yr Child1 – 12 yr Adolescent12 – 20 yr Adult20 – 70.
2012 State of the Science Congress on Nursing Research Jeanne Alhusen 1, Deborah Gross 1, Matthew Hayat 2, and Phyllis Sharps 1 1 Johns Hopkins University.
PK/PD Modeling in Support of Drug Development Alan Hartford, Ph.D. Associate Director Scientific Staff Clinical Pharmacology Statistics Merck Research.
Nonlinear Pharmacokinetics
© 2010 Universitair Ziekenhuis Gent Population pharmacokinetics of tacrolimus in stable paediatric renal transplant recipients translated into clinical.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 8 Individual Variation in Drug Responses.
Bioavailability Dr Mohammad Issa.
Population Pharmacokinetic Characteristics of Levosulpiride and Terbinafine in Healthy Male Korean Volunteers Yong-Bok Lee College of Pharmacy and Institute.
APPLICATION OF INDIVIDUALIZED BAYESIAN UREA KINETIC MODELING TO PEDIATRIC HEMODIALYSIS Olivera Marsenic, Athena Zuppa, Jeffrey S. Barrett, Marc Pfister.
Model structure  Law of mass action applied to describe the reversible solifenacin-AGP, solifenacin-albumin and solifenacin-VBC binding  VBC positioned.
VARIABILITY IN PHARMACOKINETICS & PATIENT RESPONSE Dr. Mohd B. Makmor Bakry, Ph.D., RPh Senior Lecturer in Clinical Pharmacy Universiti Kebangsaan Malaysia.
Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.
Noncompartmental Models. Introduction The noncompartmental approach for data analysis does not require any specific compartmental model for the system.
Cystic Fibrosis Patients are Pharmacokinetically Comparable to Healthy Volunteers J. Bulitta 1, S. B. Duffull 2, M. Kinzig-Schippers 1, U. Holzgrabe 3,
AN EXAMPLE OF APPLICATION OF THE POPULATION APPROACH TO TOXICOLOGICAL STUDIES F. Fiorentini 1, M. Simeoni 2, I. Poggesi 1, G. Westerberg 1, M. Rocchetti.
BACKGROUND OBJECTIVES DESIGN / METHODS DISCUSSION AND CONCLUSIONS The PPK model is well predicted; pediatric anti-Xa exposure of dalteparin is well characterized.
Background Conclusions low weight, CYP3A5*1 allele, low gamma glutamyl transpeptidase and low hematocrit are associated with a higher tacrolimus clearance.
Pharmacokinetics of Vancomycin in Adult Oncology Patients Hadeel Al-Kofide MS.c; Iman Zaghloul PhD; and Lamya Al-Naim PharmD Department of Clinical Pharmacy,
INTERMITTENT IV VANCOMYCIN WHAT DOSE SHOULD WE START WITH?
Copyright ©2008 by Pearson Education, Inc. Upper Saddle River, New Jersey All rights reserved. Focus on Pharmacology, First Edition By Jahangir Moini.
1.Andersson, T, et al. Clin Pharmacokinet 2001;40: Hassan-Alin, M, et al. Eur J Clin Pharmacol 2000;56: Population Pharmacokinetic Modelling.
PHT 415 BASIC PHARMACOKINETICS
Donepezil. Donepezil Generic name: Donepezil. Brand name: Aricept. Chemistry: Donepezil hydrochloride is a piperidine derivative. It is a white crystalline.
Infant Feeding Practices Study II Methods American Public Health Association November 5, 2007 Sara B. Fein, Judith Labiner-Wolfe, Katherine Shealy, Ruowei.
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Rivaroxaban: A Comparison of Once- and Twice-daily Dosing in Patients Undergoing Total Hip Replacement.
Copyright © 2008 Merck & Co., Inc., Whitehouse Station, New Jersey, USA All rights Reserved Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Raltegravir.
| Web: The findings and conclusions in this report are those of the authors and do not necessarily represent the official.
Drug efficacy is questioned.. Variation in drug responses.
Maternal Substance Use During Pregnancy and Increased Risk of SIDS among African Americans Fern R. Hauck, M.D., M.S. 1,2 Mark E. Smolkin, M.S. 2 University.
Genotype-directed dosing for Efavirenz
IMPAACT 2001 STUDY Mhembere T.P. (B. Pharm (Hons), MPH)
Temocillin pharmacokinetics in healthy volunteers
Chapter 9 PHARMACOKINETICS VARIABILITY
Identification of optimal dose and dosing regimen of clofazimine for the treatment of multi-drug resistant tuberculosis (MDR-TB) based on pharmacokinetic.
Pharmacokinetics of Vancomycin in Adult Oncology Patients
Lecture-8 Biopharmaceutics
Drug Therapy in Geriatric Patients
Quantitative Pharmacokinetics
BAYESIAN THEORY WITH ADAPTIVE METHOD OR DOSING WITH FEEDBACK
The MDRD Study.
The Utilization of Sequential Compression Devices Among Pregnant Women
ANALYSIS OF POPULATION KINETIC DATA
Clinical Pharmacokinetics
17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study David B. Nelson, MD; Donald D. McIntire,
A5338 P. G . MARIMBE-NYATSAMBO ANNUAL RESEARCH DAY 8 APRIL 2016.
Journal reviews 이승호.
Therapeutic Drug Monitoring chapter 1 part 1
Clinical Pharmacokinetics
Medication Administration for Pediatrics
Drug Therapy in Pediatric Patients
Presentation transcript:

Azithromycin Pharmacokinetics in Pregnancy James H. Fischer, Pharm.D., FCCP May 17, 2011

Azithromycin: Background Macrolide Commonly administered for community acquired respiratory, skin and gynecological infections Among 15 most frequently prescribed drugs to pregnant women (2004) Dose derived from non-pregnant women & men Practice disregards how dose requirements affected by pregnancy-related differences: –Pharmacokinetics –Functioning of immune system Piscitelli et al 1992; Andrade et al 2004; Jamieson 2006

Azithromycin: Pharmacokinetics Distinct profile Incomplete oral absorption (34%) Extensively distributes into tissues Eliminated by hepatobiliary excretion – P-glycoprotein – Multidrug resistance protein-2 (MRP-2) Only one previous PK study in pregnancy – Women from Papua-New Guinea receiving malarial prophylaxis Ballow et al 1998; Luke & Foulds 1997; Sugie et al 2004; Salmon et al 2010

Objectives Compare population pharmacokinetics of azithromycin between pregnant women and nonpregnant women of child bearing age Identify factors contributing to the inter-individual variability in azithromycin pharmacokinetics

Research Team Co-Principal Investigator Gloria Sarto, M.D., Ph.D. Brigham & Women’s Hospital, Harvard –Ruth Tuomala, M.D. –Karen McCarthy, R.N. University of Illinois at Chicago Patricia Fischer, R.N. Mitra Habibi, Pharm.D. Sarah Kilpatrick, M.D. Keith Rodvold, Pharm.D. University of Wisconsin Thomas Jenkins, M.D. Lori Wollett, R.N. University of Michigan –Janet Shier, Pharm.D., M.D. –Zan Daley, R.N. FDA Margaret Miller, Ph.D.

Methods: Study Design Pilot Study –Goals: assist in establishing structural model provide initial PK parameter estimates –12 healthy adult women of child bearing age –Traditional Multi-Dose Pharmacokinetic Study 500 mg *1, then 250 mg Q.D. for 4 days Extensive sampling performed for 96 h following last dose –Typical eligibility criteria (except allowed OC use)

Methods: Study Design Population Pharmacokinetic Study – Prospective, open-label multicenter design – Participants Women at least 18 years of age, Capable of bearing children, Receiving azithromycin for treatment of infection, and Either – Pregnant and at least 12 weeks gestational age, or – Nonpregnant and at least 3 months postpartum.

Methods: Study Design Sparse sampling strategy –5 samples collected within 4 sampling windows –First 3 with any dose, last 2 with final dose Drug intake assessed by diary and interviews

Methods: Laboratory Analysis Azithromycin Plasma Concentrations –HPLC with electrochemical detection –linear: 10 – 505 ng/ml –LLOQ: 10 ng/ml –inter-assay precision: 3.2% to 5.8%

Methods: Pharmacokinetic Analysis Nonlinear mixed effects modeling (NONMEM) with FOCE method Subjects with at least one evaluable azithromycin plasma concentration Data from healthy women included in population PK database Step 1: Identify structural (base) model Step 2: Covariate Analysis Step 3: Model validation

Covariates Body Size Measures total body weight lean body weight body mass index body surface area Continuous Variables age gestational age creatinine clearance azithromycin dose Categorical Variables pregnancy status Ethnicity study site type of infection concurrent medications oral contraceptives renal/hepatic disease administration with food healthy volunteer

Demographics Number53 pregnant (12-40 weeks GA) 25 non-pregnant Age (years)28 (18-49) Total Body Weight (kg)76 (45-178) Ethnicity African American19 Caucasian42 Hispanic9 Other8 Creatinine Clearance (ml/min)110 (37-229) Indication for Azithromycin Respiratory tract infection41 Premature rupture of membranes14 Chlamydia 8 Other 3 Healthy volunteer12

Structural Model Three-Compartment PK model Inter-individual variability (IIV) – exponential error Residual variability – proportional error Vc ka V-p1 CL D-P1 CL V-p2 [Lag time] CL D-P2

Two-Compartment Three-Compartment

Covariates: Oral Clearance (CL/F) Body Size Measures total body weight lean body weight body mass index body surface area Continuous Variables age gestational age creatinine clearance azithromycin dose Categorical Variables pregnancy status ethnicity pregnancy-ethnicity (pregnant non-African Americans) study site type of infection concurrent medications oral contraceptives renal/hepatic disease administration with food healthy volunteer

Covariate Models Oral Clearance (CL/F) CL/F = 134 L/h + (Ethn × Preg × (-51)) + (OC × (-51)) × LBW/50

Model Predicted CL/F for 50-kg Lean Body Weight (LBW) Woman SubjectsCL/F (L/h) Nonpregnant women of any race not receiving oral contraceptives 134 Pregnant African American women134 Pregnant Non-African American women83 Nonpregnant women receiving oral contraceptives (OC)83

Population PK Parameters: Model vs. Bootstrap Estimates ParameterFinal ModelBootstrap (n=1000) EstimateMedian2.5 th th Percentiles k a (h -1 ) Lag time (h) – 1.6 CL/F (l/h/50 kg LBW) – 176 Pregnancy, non-African Americans – -4 Oral Contraceptive Use – -4 CL D-P1 /F (l/h) CL D-P2 /F (l/h) V c /F (l) V P-1 /F (l) V P-2 /F (l) Inter-Individual Variability (CV, %) CL/F CL D-P2 /F (l/h) V c /F V P-1 /F Residual error (%)

Visual Predictive Check Nonpregnant women Pregnant African American women Pregnant Non-African American women Women receiving oral contraceptives

Influence of Pregnancy and Ethnicity on CL/F * * p<0.05, compared to non-pregnant women who were not receiving oral contraceptives

Influence of Oral Contraceptives on Cl/F * * p<0.05, compared to non-pregnant women who were not receiving oral contraceptives

Conclusions Ethnicity influences the effect of pregnancy on azithromycin CL/F Compared to non-pregnant women, azithromycin CL/F during pregnancy is unchanged in African American women and 40% lower in non-African Americans Concurrent administration of oral contraceptives (OCs) also reduced azithromycin CL oral

Conclusions Whether ethnicity also impacts the effect of OCs on CL/F requires further study as no African American women were in the OC cohort. These findings suggest that estrogen or progesterone mediate the effects of pregnancy and OCs on azithromycin CL/F.

Research in Pregnant Women Lessons Learned

IRB Challenges Vulnerable Population Options to Participation (other drug options) Coercion/Undue Influence Inclusions of subjects < 18 y/o Risks of Drug Therapy Restrictions on concurrent drug therapy Data Safety Monitoring Committee

IRB Challenges Frequency of Blood Sampling Translated consent forms Certificate of Confidentiality Follow up Data Collection on Newborn – Consent – Blood sampling

Overcoming Challenges Request Pre-review with IRB staff Study design: Population PK – missed clinic visit or time limitations have no impact on study integrity Be prepared for additional scrutiny

Reasons for not participating Time commitment Illness in addition to pregnancy – did not want additional burden Aversion to needle sticks Discomfort with 24 hr blood pressure monitor – Staff wore first to develop strategies

Subject Recruitment Strategies Involve Primary Physician – Assure physician that research is independent of clinical care – Provide overview to potential subject Experienced Study Coordinator Coordination with clinical care services – Other labs – Ultrasounds – Prolonged monitoring

Subject Recruitment Strategies Multiple sites – Adequate number of subjects – Diversity of population Age Ethnicity Diagnosis Liver/renal function Body size